Prot #XL184-308: A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy

  • Kuzel, Timothy Michael (PD/PI)

Project: Research project

Project Details

StatusFinished
Effective start/end date10/29/13 → 10/29/16

Funding

  • Exelixis Inc. (Prot #XL184-308)